Levosert (Levonorgestrel)

Levonorgestrel released from the IUS binds to progesterone receptors in the endometrium, cervical mucus, and the hypothalamic‑pituitary axis. This suppresses ovulation, thickens cervical mucus to block sperm, and creates an atrophic endometrium, together preventing implantation.

Levosert is supplied as a single 52 mg intrauterine system that releases approximately 20 µg of levonorgestrel per day. The exact dosing regimen, including insertion timing and duration of use, is determined by the prescribing clinician based on individual patient needs.

Levosert is contraindicated in women who are pregnant; it should be inserted only after confirming a negative pregnancy test. Limited data are available for breastfeeding, and clinicians should weigh potential risks and benefits before use in lactating women.

To order Levosert, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with oral progestin‑only pills, Levosert offers a once‑inserted, maintenance‑free option with higher typical‑use efficacy and no daily adherence. Unlike copper IUDs, it may reduce menstrual bleeding and cause fewer menstrual cramps, though copper devices have no hormonal side effects.

Levosert should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight, and physical damage until it is inserted by a qualified healthcare professional.

Levosert is inserted into the uterine cavity by a trained clinician using a sterile insertion kit. The procedure is performed in a clinical setting under aseptic conditions, and placement is confirmed by pelvic examination or ultrasound as needed.

Serious risks include uterine perforation during insertion or removal, infection such as pelvic inflammatory disease, expulsion of the device, and the rare possibility of ectopic pregnancy if contraceptive failure occurs. Prompt medical evaluation is required if any of these events are suspected.

Levosert is contraindicated in women with current pelvic infection, known or suspected uterine or cervical malignancy, unexplained vaginal bleeding, uterine anomalies that preclude proper placement, or a history of severe allergic reaction to levonorgestrel or device components.